Entities

Gretchen Piller is managing director with Invus Financial Advisors. The published role covers Global. Invus Financial Advisors manages public-equity and hedge-fund investment strategies.

Lila Brown is executive assistant with Invus Financial Advisors. The published role covers Global. Invus Financial Advisors manages public-equity and hedge-fund investment strategies.

Leslie Lake is managing director with Invus Financial Advisors. The published role covers Global. Invus Financial Advisors manages public-equity and hedge-fund investment strategies.

Jayme Samuel is executive assistant with Invus Opportunities, Invus Financial Advisors Team, based in New York. Invus Opportunities invests in private technology businesses.

Rachel Merluza is director of finance & compliance with Invus Opportunities, Invus Financial Advisors Team. The published role covers Global. Invus Opportunities invests in private technology businesses.

Carmen Taton is chief financial officer with Invus Opportunities, Invus Financial Advisors Team. The published role covers Global. Invus Opportunities invests in private technology businesses.

Sacha Lainovic is managing director with Invus Opportunities. The published role covers Global. Invus Opportunities invests in private technology businesses.

David Kahane is partner with Invus Opportunities. The published role covers Global. Invus Opportunities invests in private technology businesses.

Leticia Bombieri is investor with Invus Opportunities. The published role covers Global. Invus Opportunities invests in private technology businesses.

Pedro Saltos is investor with Invus Opportunities. The published role covers Global. Invus Opportunities invests in private technology businesses.

Udai Pal is investor with Invus Opportunities. The published role covers Global. Invus Opportunities invests in private technology businesses.

Bryan Kim is partner with Invus Opportunities. The published role covers Global. Invus Opportunities invests in private technology businesses.

Benjamin Tsai is partner with Invus Opportunities. The published role covers Global. Invus Opportunities invests in private technology businesses.

Cassie Wang is administrative manager with administration, based in Hong Kong. The role supports the firm’s global investment operations.

Jen Xu is financial controller with administration. The published role covers Asia. The role supports the firm’s global investment operations.

Adriana Alb is director of administration with administration, based in Paris. The role supports the firm’s global investment operations.

Andrea Prieto is executive assistant , public equity with administration, based in Paris. The role supports the firm’s global investment operations.

Gabryelle Francois is executive assistant , private equity with administration, based in New York. The role supports the firm’s global investment operations.

Maxime Szwabinski is vice president of operations , public equity with administration, based in Paris. The role supports the firm’s global investment operations.

Judy Wong is executive assistant with administration. The published role covers United States. The role supports the firm’s global investment operations.

Amanda Peso is executive assistant with administration, based in New York. The role supports the firm’s global investment operations.

Nancy Liao is executive assistant , private equity with administration, based in New York. The role supports the firm’s global investment operations.

Sophia Forde is executive assistant , public equity with administration. The published role covers United States. The role supports the firm’s global investment operations.

Michelle Lavoie is office manager with administration. The published role covers United States. The role supports the firm’s global investment operations.

Tanesha Barnett is executive assistant & private equity team coordinator , private equity with administration, based in New York. The role supports the firm’s global investment operations.

Mackenzie Walsh is operations associate , public equity with administration. The published role covers United States. The role supports the firm’s global investment operations.

John Pratt is senior operations associate , public equity with administration. The published role covers United States. The role supports the firm’s global investment operations.

Vincent Buonomo is controller , public equity with administration. The published role covers United States. The role supports the firm’s global investment operations.

Cheung Yuet Fan is a joint company secretary of WuXi AppTec. The2025 annual corporate report identifies her as an external service provider from Tricor Services Limited, a Vistra-group member, continuing alongside Min Han. This is an external corporate-secretarial appointment, not an inferred operating-company employment or expanded career biography.

Eleanor Wilson is accounting manager with administration, based in New York. The role supports the firm’s global investment operations.

Joan Carroll is tax manager with administration, based in New York. The role supports the firm’s global investment operations.

Kelly Hickey is vice president of finance with administration, based in New York. The role supports the firm’s global investment operations.

Min Han is board secretary and joint company secretary of WuXi AppTec. Appointed joint company secretary July28,2025 and boardsecretary reappointedApril28,2026. Her2025 annual biography describes bank/financial-institution and listed-company governance experience, Shanghai University accounting degree, Nottingham finance/investment masters and CPA qualifications in China and the United Kingdom.

Patrycja Poweska is senior accountant with administration, based in New York. The role supports the firm’s global investment operations.

Simona Abikova is global human resources manager with administration, based in New York. The role supports the firm’s global investment operations.

Christine Bark is compliance associate with administration, based in New York. The role supports the firm’s global investment operations.

Hunter Lite is compliance associate with administration, based in New York. The role supports the firm’s global investment operations.

Thanh Tran is compliance analyst with administration, based in New York. The role supports the firm’s global investment operations.

Xuesong Leng is an independent non-executive director and nomination committee chair of WuXi AppTec, appointedJanuary22,2025. His2025 annual biography describes prior Warburg Pincus and General Atlantic leadership, founding Lupin Capital in2015, a Shanghai Jiao Tong international-industrial-trade bachelors degree and Wharton MBA.

Arshaad Yar is chief information officer with administration, based in New York. The role supports the firm’s global investment operations.

Vanessa Lopera-Madrid is director of compliance with administration, based in New York. The role supports the firm’s global investment operations.

Zhiling Zhan is an independent non-executive director of WuXi AppTec. Her2025 annual biography describes principal-lawyer practice at Shanghai Ryser since2004, earlier Renmin University teaching and legal work at Pestalozzi and Baker & McKenzie, and law degrees from Wuhan, Renmin and the University of Tokyo.

Philip Bafundo is Invus’s chief financial officer and chief compliance officer, based in New York. His own primary biography describes prior financial leadership in asset management and accounting before joining Invus. His main-group role is distinct from Carmen Taton’s chief financial officer capacity in the Opportunities and Financial Advisors units.

Xin Zhang is an independent non-executive director of WuXi AppTec and a Fudan University accounting professor/department vice chair. His current own university biography explicitly corroborates the WuXi appointment and his Shanghai Jiao Tong bachelors/masters and Queens University finance doctorate. His research covers corporate finance, analysts and international accounting/finance.

Bohan Xue is senior associate with Public Equity, based in Hong Kong. The role supports Invus’s public equity investment activities.

Christine Shaohua Lu-Wong is an independent non-executive director and audit committee chair of WuXi AppTec. Her2025 annual corporate biography describes senior listed-company CFO/finance roles at WuXi PharmaTech, Pactera, Xueda and WuXi Biologics, U.S. CPA qualification, a Guangdong foreign-trade/economics degree and Golden Gate University accounting MBA. Historical CFO positions are not treated as current executive roles.

David Van Zandt is global general counsel with administration, based in New York. The role supports the firm’s global investment operations.

Jiahui Liu is associate with Public Equity, based in Hong Kong. The role supports Invus’s public equity investment activities.

Wei Yu is lead independent non-executive director of WuXi AppTec, elected lead director effectiveApril28,2026. His2025 annual biography describes more than30years in health management/policy research, Shanghai Chuangqi Health Development Academy leadership, prior research roles at U.S./Chinese universities and health institutions, and Shanghai University of Finance and Economics public-economics leadership. He holds an electrical-automation bachelors degree and Clemson economics masters/doctorate.

Yibing Wu is a non-executive director of WuXi AppTec. His2025 annual corporate biography describes prior McKinsey senior partnership and Asia-Pacific M&A leadership, Lenovo/Legend leadership, CITIC Private Equity/Goldstone leadership, and Temasek China leadership since joining in2013. He holds a Harvard biochemistry PhD and USTC molecular-biology degree. His historical WuXi Biologics directorship is not asserted current.

Salim Salam is director with Public Equity, based in Hong Kong. The role supports Invus’s public equity investment activities.

Thomas Dargent is an Invus public equity analyst in Paris, focused on biotechnology. Before joining in2024, he worked in healthcare and innovation, including co-founding a software platform addressing medicine shortages. He holds a pharmacy doctorate from Université Grenoble Alpes and studied entrepreneurship at HEC Paris and École Polytechnique.

Xiaomeng Tong is a non-executive director of WuXi AppTec. His2025 annual corporate biography describes Morgan Stanley investment analysis, senior Greater China roles at General Atlantic and Providence Equity, and managing partner at Boyu since2011. He holds a Harvard economics degree.

Antoine Barouky is an Invus venture partner working across the public and private healthcare teams. He joined in2023 after building and leading European operations for Alnylam, Shire, Cubist and Forest Laboratories, and earlier held business development leadership at Stallergenes. He studied biotechnology engineering at INSA Lyon and finance at HEC Paris.

Etienne Daher is a senior associate on Invus’s Paris public equity team. Before joining in2024, he was a biotechnology equity analyst at Aescap, chief of staff at Sensorion and a healthcare startup manager at Bpifrance. He holds a pharmacy doctorate from Université Grenoble Alpes and a strategy and international business master’s from ESSEC.

Isaac Sassoon is an associate on Invus’s New York public equity team. He joined in2023 after biopharmaceutical development and commercialization consulting at LifeSci Consulting. He studied economics and pre-medicine at Cornell and biotechnology at the University of Pennsylvania, where he supported cellular immunotherapy research.

Julien Miara is a managing director leading Invus’s public equity team in Europe from Paris. He joined the firm in2010 and became the European team lead in2018. His investment experience includes biotechnology, software, semiconductors and automotive businesses. Earlier he worked in investment banking and consulting; he studied management at EDHEC.

Olivier Gueymard is principal with Public Equity, based in Paris. The role supports Invus’s public equity investment activities.

Ryan Storgard is associate with Public Equity, based in New York. The role supports Invus’s public equity investment activities.

Shubham Chatterjee is an associate investing in public companies from Invus’s New York office. Before joining in2024, he worked in healthcare consulting at Boston Consulting Group and completed biotechnology investment and business development internships. He studied chemical and biological engineering at Princeton, bioengineering at the University of Pennsylvania and business at Wharton.

Louccas Bou Jaoude is senior associate with Public Equity, based in New York. The role supports Invus’s public equity investment activities.

Dylan Drakes is senior associate with Public Equity, based in New York. The role supports Invus’s public equity investment activities.

Brian Aronson is vice president with Public Equity, based in New York. The role supports Invus’s public equity investment activities.

Brittany Sacks is a director on Invus’s public equity team in New York. Before joining in2017, she covered biotechnology in equity research at J.P. Morgan and worked in Pfizer business development on acquisitions, collaborations and licensing. She studied applied economics and management at Cornell University.

Elena Devoy is global head of capital formation with Public Equity, based in New York. The role supports Invus’s public equity investment activities.

Nadim Razzouk is principal with Public Equity, based in New York. The role supports Invus’s public equity investment activities.

Quentin Langlois is a director on Invus’s public equity team in New York, focused on private biotechnology investing. Before joining in2025, he was a vice president at H.I.G. BioHealth Partners and held business development and strategy roles at Shire, aTyr Pharma and Theravance Biopharma. He studied law at UVSQ and management at HEC Paris.

Robert Mikesell is principal with Public Equity, based in New York. The role supports Invus’s public equity investment activities.

Sunny Shah is a New York-based Invus director investing in public and private biotechnology companies across development stages and therapeutic areas. He joined Invus in2020 after academic cardiology work at Weill Cornell Medicine and New York Presbyterian Hospital. His medical training includes New York University and a cardiovascular fellowship at Cornell.

Jonathan Luick is chief operating officer with Public Equity. The published role covers United States, Europe, Asia. The role supports Invus’s public equity investment activities.

Khalil Barrage is managing director with Public Equity, based in New York. The role supports Invus’s public equity investment activities.

Sumit Goenka is senior associate with Private Equity. The published role covers Asia. The team works with private companies and their leadership.

Vishal Medida is senior associate with Private Equity. The published role covers Asia. The team works with private companies and their leadership.

Francis Cukierman is managing director with Private Equity, based in Hong Kong. The team works with private companies and their leadership.

Jimmy Wu is director with Private Equity, based in Hong Kong. The team works with private companies and their leadership.

Veronica Yingying Li is director with Private Equity, based in Hong Kong. The team works with private companies and their leadership.

Corentin Le Garo is senior associate with Private Equity, based in Paris. The team works with private companies and their leadership.

Judith Levy is associate with Private Equity, based in Paris. The team works with private companies and their leadership.

Louis Loze is director with Private Equity, based in Paris. The team works with private companies and their leadership.

Victor Doussineau is managing director with Private Equity, based in Paris. The team works with private companies and their leadership.

Benedetto Staccia is managing director with Private Equity, based in Paris. The team works with private companies and their leadership.

Luc Ta-Ngoc is managing director with Private Equity, based in Paris. The team works with private companies and their leadership.

Mario Kaloustian is managing director with Private Equity, based in Paris. The team works with private companies and their leadership.

Colin Walton is analyst with Private Equity, based in New York. The team works with private companies and their leadership.

Ian Springer is associate with Private Equity, based in New York. The team works with private companies and their leadership.

Arda Sonmez is senior associate with Private Equity, based in New York. The team works with private companies and their leadership.

Charles Lefkowicz is associate with Private Equity, based in New York. The team works with private companies and their leadership.

Robert A. Belfer is listed on the Alzheimer’s Drug Discovery Foundation’s Emeritus Board of Directors in its Honorary Governors group. The foundation lists the outside professional affiliation: Chairman Emeritus, Belfer Management LLC. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Sally Susman is listed on the Alzheimer’s Drug Discovery Foundation’s Emeritus Board of Directors in its Honorary Governors group. The foundation lists the outside professional affiliation: Executive Vice President, Policy, External Affairs and Communications, Pfizer Inc. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Vishesh Shah is associate with Private Equity, based in New York. The team works with private companies and their leadership.

Justice Sandra Day O'Connor is listed on the Alzheimer’s Drug Discovery Foundation’s Emeritus Board of Directors in its Governors in Memoriam group. The foundation lists the outside professional affiliation: Associate Justice, US Supreme Court. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Melvin R. Goodes is listed on the Alzheimer’s Drug Discovery Foundation’s Emeritus Board of Directors in its Governors in Memoriam group. The foundation lists the outside professional affiliation: Former Chairman and Chief Executive Officer, Warner-Lambert. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Samantha Speer is senior associate with Private Equity, based in New York. The team works with private companies and their leadership.

Jared Smith is director, data strategy and analytics with Private Equity, based in New York. The team works with private companies and their leadership.

Leonard A. Lauder is listed on the Alzheimer’s Drug Discovery Foundation’s Emeritus Board of Directors in its Governors in Memoriam group. The foundation lists the outside professional affiliation: Chairman Emeritus, The Estée Lauder Companies Inc.. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Wendy L. Wilshin is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Founder and Principal, WLW Designs. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

David Nielsen is director with Private Equity, based in New York. The team works with private companies and their leadership.

Elise Gelman Lefkowitz is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Philanthropist. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Gregory A. Rosica is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Retired Partner, Tax, Ernst & Young, LLP. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

John H. Scully is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Senior Managing Director and Head of Private Wealth Advisory, Nuveen Investments. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Julie Medler is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Retired Managing Director, JPMorgan. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Justin Meltzer is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Real Estate Operations, DLA Piper LLP. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Phebe Farrow Port is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Senior Vice President, Global Management Strategies, and Chief of Staff, Executive Management Initiatives, The Estée Lauder Companies, Inc.. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Philip Lovett is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Founding Partner, Millennium Partners. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Stephen Toma is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Investor and Philanthropist. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Tom Scanlan is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Partner, Spencer Stuart. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Allan M. Green is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Allan M. Green Esq., LLC. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Benjamin Felt is managing director with Private Equity, based in New York. The team works with private companies and their leadership.

Clare Joyce is a managing director on the Invus private equity team, published with United States and Asia responsibilities. Her current own biography and portrait identify the investment professional; no unreported personal investment or exact appointment day is inferred.

Dave Gerson is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Personal Financial Planning Consultant, Retired Tax Partner Ernst & Young, LLC. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Gina F. Fochetta is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Executive Director, J.P. Morgan Private Bank; Co-Founder and Co-Chair, ADDF Young Professionals Committee. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Joel Florin is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: President, Micro Essential Laboratory, Inc.. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Josh Lauder is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Co-Founder and Co-Chair, ADDF Young Professionals Committee. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Justin Barstein is managing director with Private Equity, based in New York. The team works with private companies and their leadership.

Michael Dubin is director with Private Equity, based in New York. The team works with private companies and their leadership.

Mitchell D. Eichen is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Former Founder and Chief Executive Officer, Acertus Capital Management; Former Founder and Chief Executive Officer, The MDE Group. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Mitchell Kaneff is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Chairman and Chief Executive Officer, Arkay. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Stephanie Ginsberg is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Volunteer, Philanthropist; Founder, BCRF Pink Promises Benefit. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Aflalo Guimarães is managing director with Private Equity, based in New York. The team works with private companies and their leadership.

Bal Agrawal is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Founder and Chief Executive Officer, LifeWorx, Inc.; Founder and Chief Executive Officer, Prima Chefs, Inc.. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Charles Cangro is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Former Principal, Personal Financial Services, Ernst & Young, LLP. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Charlie Lefkowitz Crowley is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Educational Consultant and Philanthropist. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Evren Bilimer is managing director with Private Equity, based in New York. The team works with private companies and their leadership.

Kristin Rae Cecchi is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Overseers group. The foundation lists the outside professional affiliation: Marketing Design Consultant, Cecchi Homes. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Alice Shure is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Founder and Producer, AMICI Productions LLC; Co-Trustee, The Charles Evans Foundation. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Anthony (Nino) Sireci is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Sr. Vice President, Clinical Biomarkers, Laboratories and Diagnostics, Eli Lilly and Company. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Bonnie Lautenberg is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Photographer and Writer, Bonnie Lautenberg Designs. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Christopher Johnson is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Overseers in its Chair group. The foundation lists the outside professional affiliation: President, Rackson Companies. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Christopher Sobecki is managing director with Private Equity. The published role covers United States. The team works with private companies and their leadership.

David R. Weinreb is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Chief Executive Officer, Weinreb Ventures. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Jonas Fajgenbaum is managing director with Private Equity, based in New York. The team works with private companies and their leadership.

Julieann Shanahan is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Creator, Pavilion Living: Architecture, Patronage and Well-Being. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Laurence C. Leeds, Jr. is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Former Chairman, Buckingham Capital Management, Inc.. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Paula Zahn is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Host and Executive Producer, Discovery ID's "On the Case with Paula Zahn," and WNET's "NYC Arts". This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Philippe Amouyal is managing director with Private Equity, based in Miami. The team works with private companies and their leadership.

Raymond Debbane founded Invus in1985 and is its President and CEO, based in New York. He also leads the Artal Group. Earlier he was a Boston Consulting Group manager in Paris. He holds an MBA from Stanford, a food science and technology master’s from UC Davis, and agricultural science and engineering degrees from the American University of Beirut. His charity and institutional affiliations are distinct from an institutional cash investment.

Richard C. Mohs is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Co-Chair, Scientific Investment Approval Committee. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Sharon T. Sager is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Chair, Finance and Audit Committee. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Adam Hoffman is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Co-Chair, Mission Related Investment Committee. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Ann Jackson is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Philanthropist. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Bonnie Pfeifer Evans is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Senior Sales Associate, Corcoran Group Real Estate; Co-Trustee, The Charles Evans Foundation. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Lanny Edelsohn is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Neurology Professor Emeritus, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Nancy Corzine is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: President and Chief Executive Officer, Nancy Corzine, Inc.. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Nancy Goodes is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Former Executive, Nazareth-Century Mills; Secretary, Melvin R. Goodes Family Foundation, Inc.. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Rachid Izzar is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Executive Vice President, Global Product Strategy and Commercialization, Biogen, Inc.. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Carol Seabrook Boulanger is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Partner, Pillsbury, Winthrop, Shaw, and Pittman, LLP. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Daniel Gross is Controller at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Finance + Mission Related Investments; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

David Silver is Senior Director Philanthropy and Partnerships at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Philanthropy + External Affairs; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Edward Prunchunas is listed in Coronet Ventures’ current public directory as Board member (Cedars-Sinai Intellectual Property Company board). This affiliation belongs to the Cedars-Sinai-linked international healthcare investment platform. The published regional, adviser or board scope is preserved; no joining date or personal investment is inferred.

Emily Berkowitz is Senior Director, Communications at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Communications; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Gavin Cook is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Executive Director, Global Alzheimer’s Disease Commercial, Patient Journey and Project Management Head, Eisai US. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

James Laur is listed in Coronet Ventures’ current public directory as Board member (President, Cedars-Sinai Intellectual Property Company). This affiliation belongs to the Cedars-Sinai-linked international healthcare investment platform. The published regional, adviser or board scope is preserved; no joining date or personal investment is inferred.

Julia Leonard is Manager, Communications at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Communications; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Katie Mischik is Chief of Staff and Operations at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Operations + Administration; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Lakita Cavin is Senior Attorney, Mission Related Investments at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Finance + Mission Related Investments; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Marina D'Emic is Chief Financial Officer at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Finance + Mission Related Investments; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Michael Dooijes is listed in Coronet Ventures’ current public directory as Strategic Advisor — Netherlands. This affiliation belongs to the Cedars-Sinai-linked international healthcare investment platform. The published regional, adviser or board scope is preserved; no joining date or personal investment is inferred.

Peter Post is listed in Coronet Ventures’ current public directory as Strategic Advisor — Netherlands. This affiliation belongs to the Cedars-Sinai-linked international healthcare investment platform. The published regional, adviser or board scope is preserved; no joining date or personal investment is inferred.

Randal Sandler is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Vice Chairs group. The foundation lists the outside professional affiliation: Chair, Executive Committee Chair, Compensation Committee. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Roberta Diaz Brinton is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Governors group. The foundation lists the outside professional affiliation: Co-Chair, Scientific Investment Approval Committee. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Ronald S. Lauder is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Chair group. The foundation lists the outside professional affiliation: Chairman, Clinique Laboratories, LLC. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Stephanie Dunphy is Manager, Scientific Operations and Executive Assistant at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Operations + Administration; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Thomas F. McWilliams is listed on the Alzheimer’s Drug Discovery Foundation’s Board of Governors in its Vice Chairs group. The foundation lists the outside professional affiliation: Co-Chair, Mission Related Investment Committee. This is a foundation governance or honorary affiliation, not an assertion of operating employment.

Allison Ruttley is Major Gifts Officer at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Philanthropy + External Affairs; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Christine Scerra is Senior Director, Special Events and Development Operations at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Philanthropy + External Affairs; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

David Wrigley is listed in Coronet Ventures’ current public directory as Board member (Cedars-Sinai Health System EVP and CFO). This affiliation belongs to the Cedars-Sinai-linked international healthcare investment platform. The published regional, adviser or board scope is preserved; no joining date or personal investment is inferred.

Jenna Iachetti is Senior Manager, Special Events at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Philanthropy + External Affairs; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Koen van Breugel is listed in Coronet Ventures’ current public directory as Investment Director — Netherlands. This affiliation belongs to the Cedars-Sinai-linked international healthcare investment platform. The published regional, adviser or board scope is preserved; no joining date or personal investment is inferred.

Alex Chai is listed in Coronet Ventures’ current public directory as Vice President and General Counsel. This affiliation belongs to the Cedars-Sinai-linked international healthcare investment platform. The published regional, adviser or board scope is preserved; no joining date or personal investment is inferred.

Betsy Mills is Associate Director, Aging and Alzheimer’s Prevention at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Colin Tan is listed in Coronet Ventures’ current public directory as Investment Director and Data Protection Officer — Singapore. This affiliation belongs to the Cedars-Sinai-linked international healthcare investment platform. The published regional, adviser or board scope is preserved; no joining date or personal investment is inferred.

Jennifer Panlilio is Program Officer, Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Jerica Reeder is Assistant Director, SpeechDx, Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Katie Dolan is Senior Manager, External Affairs at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Philanthropy + External Affairs; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Melissa Lee is Director, Diagnostics Accelerator, Digital & AI at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Olga Kahn is Director, Fluid Biomarkers, Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Coronet Ventures is Cedars-Sinai Intellectual Property Company’s international healthcare and biomedical investment initiative. The Singapore platform was announced in May 2023 as Coronet Ventures (Singapore) Pte. Ltd., a co-investment partner of SEEDS Capital under Startup SG Equity. The current brand also covers Coronet Ventures Netherlands, launched in June 2025; its Dutch alternative-fund manager is CV PB Management Company B.V. These regional legal entities are qualified within the shared platform rather than conflated with Cedars-Sinai Medical Center or another pharmaceutical investor. Coronet targets early-stage healthcare and biomedical companies with potential for the U.S. market, connecting portfolio companies to Cedars-Sinai clinical validation, research, commercialization and accelerator resources. Its current published investment strategy is Seed and Series A, with indicative checks of US$500,000–3 million. Its portfolio includes AI drug discovery and respiratory monitoring, medical devices and digital health. CEO Nirdesh Gupta leads the initiative; the published regional teams, advisers and board affiliations are explicitly scoped. The Netherlands strategy’s announced US$50 million deployment over ten years is not a verified closed LP fundraise, and the parent’s equity assets are not Coronet fund capital.

Jennifer Hsiao-Nakamoto is Senior Program Officer, Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Yuko Hara is Director, Aging and Alzheimer’s Prevention at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Chandra Gruber is Director, Grants Management at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Marisa Goo is Assistant Director, Search and Evaluation at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Jessica Gallegos is Project Manager, Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Tyler Demarest is Director, Search and Evaluation at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Aaron Burstein is Head, Search and Evaluation at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Kathryn Carnazza is Program Officer, Aging and Alzheimer's Prevention at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Mollie Boettcher is Manager, Grant Operations at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Search & Evaluation; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Jane McIntosh is Chief Philanthropy and External Affairs Officer at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Executive; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Laura Nisenbaum is Interim Chief Science Officer at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Executive; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Isobel Coleman is Chief Executive Officer at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Executive; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias. Her official biography describes previous McKinsey partnership and twice Senate-confirmed diplomatic service, with a PrincetonBA and OxfordMPhil/DPhil in InternationalRelations.

Karen Harris is Executive Director, Mission Related Investments and Finance at the Alzheimer’s Drug Discovery Foundation. The foundation’s public staff directory places this role in Executive; its work supports research, mission-related investments and philanthropy for Alzheimer’s disease and related dementias.

Phyllis Barkman Ferrell is an ADDF Board of Overseers member, listed as ChiefImpactOfficer for StartUpHealth’s Alzheimer’sMoonshot, SeniorConsultant to GatesVentures and independent adviser at PBFerrell LLC. StartUpHealth’s current own team directory identifies the same full name and original portrait, and her previous role leading external engagement for Alzheimer’s and neurodegeneration at EliLilly. ADDF’s public overseer biography identifies Phyllis Barkman Ferrell as a senior consultant to Gates Ventures LLC alongside her independent consulting business and Alzheimer’s Moonshot work at StartUp Health. This is an external consulting affiliation, rather than an assertion that she is a Gates Ventures employee.

Chief academic officer directing graduate and medical-student education, faculty development and research administration. SUNY Downstate MD with Boston University internal-medicine training and epidemiology master’s. Published Northwell affiliation: Senior VP & Chief Academic Officer; Betsey Cushing Whitney Professor of Medicine.

Associate professor at Feinstein’s Institute of Bioelectronic Medicine and leader of the Translational Neurophysiology Laboratory. Studies autonomic neural circuits, immune physiology and therapeutic neuromodulation. Trained in medicine in Thessaloniki and neuroscience/physiology at Washington. Published Northwell affiliation: Associate Professor, Institute of Bioelectronic Medicine, Feinstein Institute for Medical Research.

Current Northwell private-equity subcommittee board observer and Huntington Hospital chair emeritus; former system trustee and private-equity subcommittee chair. Founder/managing partner of Northwell Health Equity Partners. Separate external investment-management employment is not treated as Northwell staff or a new fund closing. Published Northwell affiliation: Board Observer, Northwell Private Equity Subcommittee; Chair Emeritus, Huntington Hospital (qualified affiliations).

Current OMVC Associate based in Singapore, leading investment efforts across Southeast Asia and supporting APAC portfolio businesses. Previously worked at Encomenda Capital Partners and studied business at ESADE in Barcelona. Joined the Vectr Fintech Partners platform in2022; its older Vectr directory’s Analyst title remains source-published history, while current OMVC uses Associate.

Northwell senior vice president and chief marketing and communications officer, responsible for brand, communications and clinical marketing. Also leads Northwell Studios. Published Northwell affiliation: Senior Vice President and Chief Marketing and Communications Officer.

Published Vectr venture partner with technology, growth-strategy and financial-policy experience. Previously worked in Microsoft advisory services and co-founded open-source intelligence business Xceed Ventures. His biography describes Saudi crowdfunding and open-banking work. Holds a King Saud University computing degree and Harvard general-management training; personal angel investments remain separate.

ATHOS KG is a German private investment holding and family office based in Holzkirchen. It invests entrepreneurially with a principal focus on pharmaceuticals and life sciences, supporting the development and commercialization of medicines through direct company investments and long-term ownership. Its operating-company holdings include pharmaceutical businesses held through subsidiaries, while its venture investments include clinical-stage biotechnology. ATHOS led the April 2026 EUR 35 million financing of TIBEAY BioSciences to advance an investigational treatment for severe traumatic brain injury. The legal entity is ATHOS KG, Munich commercial register HRA 110419; subsidiary Santo Holding (Deutschland) GmbH and other ATHOS-branded legal entities remain distinct organizations.

MIG Capital AG is a Munich-based venture capital investment manager backing European deep technology and life science companies. It evaluates scientific and technical discoveries, provides growth capital and supports founders with commercial strategy, governance and international investor networks. Its investment areas include advanced computing, industrial digitalization and IoT, energy and environmental technologies, new materials, biopharmaceutical therapeutics, medical technology and digital health. The firm manages the MIG Funds, which enable private investors to participate through closed-end investment partnerships. Founded in 2004, it typically invests EUR 1–10 million per transaction, with a stated sweet spot of EUR 3–5 million. MIG Capital is the external investment manager; HMW organizations separately handle fund structuring and fundraising.

Published co-founder and managing partner of Vectr Carbon Partners, with a climate-technology venture-partner affiliation to Vectr. His source biography describes international work in energy, agriculture, waste and technology, and an operating-partner role at Nexus PMG. Studied at Stanford, the University of Pennsylvania and Jochi University. External affiliations are source-published rather than independently recertified for 2026.

Published Vectr venture partner with experience expanding Airbnb into Asia and helping launch its Experiences and social-impact initiatives. Previously co-founded restaurant chain Chickenow. This identity is distinct from Vectr co-founder Alan Chan.

Physician-in-chief and Zucker medical-school dean; formerly Northwell chief medical officer. Founding medical-school educator and former vice dean. Published Northwell affiliation: Physician-In-Chief and Dean of the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

Published Vectr venture partner with experience in Israeli technology and international startup partnerships. Founded Upround Ventures and previously worked at theglobe.com; the directory describes advisory work for Nielsen Innovate and interest in digital health. Holds a Kellogg MBA. Undated external affiliations remain source-qualified.

Published Vectr venture partner and media entrepreneur. His biography describes founding roles at 88rising, Stampede Ventures and East West Ventures, plus involvement with Triller and Asian entertainment investments. These undated outside roles are source-published history, and his personal investments are not assigned to Vectr.

Executive vice president and chief operating officer, confirmed by HANYS’ 2026 board announcement. Previously led Northwell’s Western Market. Holds Dartmouth healthcare-delivery science MS, Hofstra MBA and Stony Brook BA. The forum heading says COO while its biographical paragraph retains older COO-elect wording; newer primary evidence resolves the title. Published Northwell affiliation: Executive Vice President and Chief Operating Officer (current 2026 HANYS source).

Emergency-medicine chair and Feinstein investigator studying resuscitation, reperfusion and cellular injury. Previously founded resuscitation programmes at Pennsylvania and Chicago; earned his MD at Illinois. Published Northwell affiliation: Chair, Emergency Medicine, Northwell Health; Feinstein Institutes for Medical Research.

Chair of Northwell’s board of trustees. Public-health leader and Columbia executive in residence; formerly led JSI, Partnership with Children and AFS-USA. Holds Harvard MBA, Columbia MPH and Princeton BA. Published Northwell affiliation: Chair, Board of Trustees.

Co-founder and managing partner of Vectr Fintech Partners, subsequently OMVC, with a published Vectr venture-partner affiliation since 2014. Experience includes financial-services technology ventures, acquisitions and government consulting. Holds government and philosophy degrees from William & Mary. Own February 2025 announcement confirms the fintech-platform rebrand; it does not rename all Vectr Ventures.

Published Vectr operating partner focused on strategy, operations and capital solutions. His career includes Goldman Sachs Asia M&A, strategy leadership at the NBA and NBA China, and senior leadership at Vobile. Holds a Wharton MBA and Washington University undergraduate degree.

Published venture partner of the related Vectr Fintech Partners platform, subsequently OMVC. His biography describes fintech operations work involving WalletConnect, 11:FS and Monzo, following banking and capital-markets advisory work at PwC. No independently verified current bank employment is inferred.

Vectr Ventures co-founder and partner focused on China sourcing and investor relations. Previously a software engineer at IBM Canada and worked in financing and alternative investments at R&F Properties. Studied computer science at the University of Waterloo.

Vectr Ventures co-founder and managing partner responsible for investment strategy. Earlier experience includes Goldman Sachs investment banking, ITC Corporation alternative investments, and founding entertainment-ticketing company iPiao. Duke University graduate.

Co-founder and general partner of Vectr Ventures, leading strategy, growth and portfolio support. Also co-founded Vectr Fintech Partners and Hong Kong accelerator Betatron. Holds a business degree from Loyola Marymount and an MBA from the University of San Francisco.

Current OMVC Principal, confirmed by the manager’s public team page. Leads sourcing, investment diligence, company support, market research, financial analysis and internal technology projects. Before joining the Vectr Fintech Partners platform, he built fintech products at Fidelity Labs. Holds engineering-management and engineering degrees from Dartmouth and a physics degree from Bowdoin. Earlier source-published Vectr analyst and2025 associate titles are historical relative to the current Principal title.

Emergency and aerospace-medicine physician leading Northwell emergency telehealth. Studied at Drake and New York Medical College, trained in North Shore emergency medicine and aerospace medicine at King’s College. Official page caption identifies Bryan McCarty despite the portrait filename spelling Brian McCarthy. Published Northwell affiliation: Physician Lead, Northwell Emergency Telehealth Services; concurrent MDONBOARD Medical Director.

Vectr’s published technology managing director and studio co-head, with responsibility for technology diligence. Joined in 2014 and co-founded Area28 as CTO. Previously a senior computer scientist at Adobe, working on Acrobat and document technology. Berkeley electrical engineering and computer science graduate.

Published Vectr investor-relations associate who joined in 2022. Earlier work includes fund placements, ION Group relationship management and Swire Hotels. Holds a business-administration degree from the University of Edinburgh.

Co-founder of Vectr Fintech Partners, subsequently OMVC, and a published Vectr venture partner since 2014. Technology entrepreneur and co-author of the securities-crowdfunding framework used in the US JOBS Act. Co-founded Crowdfund Capital Advisors and previously worked in healthcare software. The 2025 OMVC presentation confirms managing-partner status at the related fintech platform.

Published finance and operations managing director, overseeing finance, investment diligence and portfolio monitoring. Joined Vectr in 2017 after senior-manager work for private-equity and venture clients at Ernst & Young and accounting firms in New York. Licensed New York CPA.

Leads Northwell coordinated acute care, emergency telehealth, patient transfer and EMS medical programmes. Holds Northwestern bachelor’s in cognitive neuroscience and artificial intelligence, SUNY Downstate MD, UCLA emergency training and Hofstra executive MBA. Published Northwell affiliation: Vice President, Transfer and Acute Coordinated Care; Medical Director, Emergency Telehealth Services.

Neurosurgeon and research executive studying neural regulation of immune responses and bioelectronic medicine. Co-founded SetPoint Medical, but this career affiliation alone does not establish a Northwell corporate investment. Holds Boston College chemistry BS and Boston University MD; trained in neurosurgery at New York Hospital–Cornell. Current Northwell and Feinstein roles independently published in his own United Therapeutics board biography. Published Northwell affiliation: Executive Vice President, Research; President and CEO, Feinstein Institutes for Medical Research.

Joined Northwell in 2021 to lead fixed-wing organ-transplant aviation operations. Aviation executive with an Embry-Riddle degree; this is a qualified subsidiary operational role, not venture investment management. Published Northwell affiliation: Director, Flight Operations, North Shore University Hospital (Northwell subsidiary).

Published product and development managing director, studio co-head and Area28 co-founder. Joined Vectr in 2015 after graphics-engine and product leadership at Bruce Artwick Organization and Microsoft. His biography describes work on games, augmented reality and visualization, plus advising Betatron.

Joined Holdings in 2023 and oversees MDONBOARD operations. Previously led operations in Northwell clinical departments and women’s health services; holds Dowling MBA and St Joseph’s healthcare-administration bachelor’s. Published Northwell affiliation: Assistant Vice President, Northwell Holdings; concurrent MDONBOARD operations executive.

Leads communications and marketing supporting Holdings’ portfolio and innovation initiatives. Previously worked in academic-healthcare communications at SUNY Downstate; holds a Duquesne business degree. Published Northwell affiliation: Senior Director, Marketing and Communications, Northwell Holdings.

Clinician executive conducting clinical due diligence, supporting venture investments and commercializing clinical innovations. Holds Columbia nursing doctorate and master’s degrees, Cornell science master’s and Rutgers degrees; previously supported Mount Sinai clinical transformation. Published Northwell affiliation: Vice President, Clinical Solutions, Northwell Holdings.

Feng Zhang (WuXi AppTec) is Senior Vice President, API Manufacturing at WuXi AppTec. Over 20 years of experience in API manufacturing. Responsible for the build-up and operations of global API Manufacturing. Bachelor's degree in pharmaceutical from Shanghai Medical University and EMBA degree in Finance and Economics from Shanghai University.

Northwell Holdings managing director overseeing investment strategy, capital investments and portfolio management. Joined Northwell legal affairs in 2016 after M&A/private-equity work at Hughes Hubbard & Reed and Willkie Farr & Gallagher. Holds Duke JD and English MA and Richmond BA. Own 2026 Columbia event post calls her vice president of legal affairs; the 2024 appointment used assistant vice president. Distinct from the existing Cystic Fibrosis Foundation volunteer of the same name. Published Northwell affiliation: Managing Director, Northwell Holdings; Vice President, Legal Affairs (own 2026 event source).

Leads Northwell Holdings’ commercial joint ventures, spinouts and investments; formerly led operations for Northwell Ventures. Joined Northwell in 2015 after health-system, consulting and academic-healthcare leadership. Holds an English bachelor’s from Saint Michael’s and a Columbia MPH. Published Northwell affiliation: President and Chief Executive Officer, Northwell Holdings (corporate venture and innovation arm).

Xiang Wu is Senior Vice President, RCS at WuXi AppTec. Over 20 years of industry experience with proven track record in medicinal chemistry and synthetic organic chemistry. Formerly worked at AMRI. Ph.D. in Medicinal Chemistry from National University of Singapore.

Dirk Tormans is Senior Vice President, WuXi Chemistry Global QA at WuXi AppTec. Over 20 years of experience in pharmaceutical quality management, CMC development and commercial manufacturing, regulatory submissions & compliance for small as well as large molecules. Formerly Sr. Director Quality at Johnson & Johnson. Master's degree in Chemical Engineering (microbiology and process technology) from the University of Leuven, Belgium.

Physician executive leading Northwell Health Physician Partners, as stated in his September 22, 2026 American Medical Association interview about physician leadership and care culture. Published Northwell affiliation: Senior Vice President; Executive Director, Northwell Health Physician Partners (September 2026 interview).

Youchu Wang is Senior Vice President, API Early Phase Development at WuXi AppTec. Over 20 years of experience in synthetic organic chemistry and small molecule process development. Formerly Sr. Scientist of Process Chemistry at Wyeth. Ph.D.in Organic Chemistry from Chinese Academy of Science followed by Postdoctoral Research at Memorial University of Newfoundland, Canada.

Oversees Northwell financial strategy and operations, including reporting, budgeting, cash management, tax, risk and revenue cycle. CPA with Hofstra MBA and BBA; previously worked at Deloitte. Current executive title published by her Big Brothers Big Sisters of Long Island board biography. Published Northwell affiliation: Executive Vice President and Chief Financial Officer.

Ke Chen is Senior Vice President, API Late Phase Development and Commercialization at WuXi AppTec. Over 10 years of industry experience with proven track record in Organic Chemistry, small molecule API process R&D and Manufacturing, process technology transfer as well as pharmaceutical CMC development. Formerly Principal Scientist of Process Chemistry at Bristol-Myers Squibb. Ph.D. in Organic Chemistry from University of Rochester.

Nursing and health-system leader named executive vice president and president of the Eastern Market in Northwell’s Mather Hospital 2025 community-health assessment, published January 2026. Published Northwell affiliation: Executive Vice President and President, Eastern Market (2025 CHNA published January 2026).

President of Northwell’s Mather Hospital. Previously led strategic alliances and Cohen Children’s Medical Center operations. Holds an MBA from Baruch/Mount Sinai and a health-administration bachelor’s degree from the Medical College of Virginia/Virginia Commonwealth University. Subsidiary hospital leadership is qualified rather than presented as system CEO. Published Northwell affiliation: Senior Vice President; President, Mather Hospital (Northwell subsidiary).

Leads Northwell’s workforce strategy after joining in 2008. Previously practiced law and management at the New York City Mayor’s Office of Labor Relations. Holds Albany degrees in political science/Africana studies and educational administration, and a JD from New York Law School. Current title corroborated by the National Center for Healthcare Leadership’s April 2026 board publication. Published Northwell affiliation: Senior Vice President and Chief People Officer.

Tao Guo is Senior Vice President, RCS IPM at WuXi AppTec. Over 20 years of experience in drug discovery, recipient of over 40 US issued patents and inventor of one FDA approved drug. Formerly Director of Chemistry at Pharmacopeia and Senior Research Scientist at ARIAD Pharmaceuticals. Ph.D. in Organic Chemistry from Columbia University.

Physician and public-health leader named as executive vice president of Northwell’s Institute for Community Health and Wellness in Mather Hospital’s 2025 community-health assessment published January 2026. Historical senior-vice-president titles should not replace this later published role. Published Northwell affiliation: Executive Vice President, Institute for Community Health and Wellness (2025 CHNA published January 2026).

Jinling Chen is Senior Vice President, Pharmaceutical Development and Manufacturing at WuXi AppTec. Over 20 years of experience in formulation & process development planning and strategy, drug delivery technologies, formulation, drug product process development and manufacturing, CMC regulatory submission. Holds more than 20 globally recognized patents. Formerly worked at Zeneca, BSM, Lexicon. Ph.D. in Physical Chemistry from Monash University in Australia.

Physician executive leading the Katz Institute for Women’s Health, as named in Northwell’s published 2026 Constellation Forum speaker roster. Published Northwell affiliation: Senior Vice President, Katz Institute for Women's Health.

Medical executive responsible for clinical initiatives and patient experience at Northwell’s Katz Institute for Women’s Health, as published in its 2026 Constellation Forum roster. Published Northwell affiliation: Medical Director; Vice President, Clinical Initiatives and Patient Experience, Katz Institute for Women's Health.

Yu Lu is Senior Vice President, WuXi TIDES, WuXi Chemistry Business Operations at WuXi AppTec. Over 20 years of industry experience with a proven track record in pharmaceutical CMC development, business development and marketing, new business creation as well as operations management. Previously worked at Merck and Vertex. Master's degree in chemistry from Duke University and MBA degree from Kellogg School of Management, Northwestern University.

Hao Wu is Senior Vice President, Legal Department, Human Resources Department at WuXi AppTec. Over 20 years of rich experience in the fields of legal, compliance management and cross region management in the related areas. Before joining WuXi AppTec, Dr. Wu was General Manager of Legal Department for the China region at Sinar Mas Group – Asia Pulp & Paper, and served as Chief Compliance Counsel for GE Healthcare Greater China region, General Counsel for Momentive Performance Material Asia Pacific region and a practicing lawyer in the US. Dr. Wu received Juris Doctor degree from School of Law of University of the District of Columbia. Also published as Howard Wu; legal April2026 appointment uses Hao Wu, exactmatching career and education.

Cardiologist and medical executive appointed chief medical officer in 2021. Previously led Lenox Hill Hospital after joining Northwell in 2014; earlier practiced at Mount Sinai, NYU and Beth Israel. Completed medical, residency and cardiology training at Mount Sinai. Published Northwell affiliation: Executive Vice President, Chief Medical Officer and Deputy Physician-in-Chief.

Xuanjia Peng is Senior Vice President, WuXi Testing, WuXi Biology, Automation Department at WuXi AppTec. Since joining WuXi AppTec, Dr. Xuanjia Peng has successful track records in leading business and operation units spanning drug discovery hit generation, chemistry catalog, chemistry service operation, and medicinal chemistry service. Ph.D. in Organic Chemistry from Lanzhou University.

Pediatric surgical leader and Northwell gun-violence-prevention executive sponsor. Established the Feinstein laboratory studying pediatric injury and inflammation. Studied medicine at Yale and completed surgical training in Pittsburgh. Published Northwell affiliation: Pediatric Surgeon-in-Chief; System Chief, Pediatric Surgery and Acute Care Surgery.

Ming Shi is Senior Vice President, Chief Financial Officer at WuXi AppTec. Over 20 years of rich professional knowledge and management experience in the fields of finance, business development and operations. Most recently worked at General Electric as the Managing Director of Business Development and CFO of GE China. Bachelor degree in International Finance from Shanghai University. Also published as Florence Shi; legal April2026 CFO appointment uses Ming Shi, exactmatching GE China career.

Led Northwell for 23 years before becoming CEO emeritus. His continuing advisory work includes public health, teaching and writing. Earlier served in New York state government, academia and health insurance. This emeritus affiliation supersedes historical CEO labels. Published Northwell affiliation: CEO Emeritus; advisory role (former President and CEO).

Richard Connell is US/EU President at WuXi AppTec. Over 35 years of experience in the biotech and drug discovery sector, before joining WuXi AppTec Rick was Vice President of External Research Solutions at Pfizer. Managed a global network of Contract Research Organizations, Contract Manufacturing Organizations, Biotech, technology and academic partnerships. Held multiple management positions in the U.S., UK, Germany and China while at Pfizer and Bayer. Ph.D. in Organic Chemistry from University of Notre Dame.

Xiaoyong Fu is Executive Vice President, STA at WuXi AppTec. Over 30 years of experience in Organic Chemistry, small molecule API process R&D and Manufacturing, Process technology transfer as well as overall CMC. Formerly Sr. Fellow of Process Chemistry at Schering-Plough/MSD. Ph.D. in Organic Chemistry from University of Wisconsin-Milwaukee.

Emergency physician who became Northwell president and CEO on October 1, 2025. Previously led its central region and emergency-medicine operations; coordinated pandemic operations. Studied medicine at Stony Brook and trained in emergency medicine at Geisinger; served in the US Army Reserve. Published Northwell affiliation: President and Chief Executive Officer (effective October 1, 2025).

Physician and translational scientist with prior protein-therapeutics, gene-therapy and clinical-development leadership at BioMarin, Audentes and Taysha.

Flux Therapeutics develops genetic medicines for haploinsufficiency and other inherited disorders that are difficult to address with existing gene therapies. Its platform combines targeted ubiquitin modulators, or TUMs, with other therapeutic technologies to overcome limitations of first-generation genetic medicines. Haploinsufficiency occurs when a single functional copy of a gene does not provide enough gene product for normal biological function. The company is a Scion Life Sciences portfolio business. The public site describes a development platform rather than approved medicines and does not disclose an approved product, specific clinical program or completed trial.

Daupler develops response-management software for utilities, public works departments and other organizations maintaining critical infrastructure. Its cloud platform collects service requests and emergency reports, uses AI to identify and triage incidents, and automates crew formation, callouts, dispatch and documentation. Customers can submit photos and updates, while operators send service notifications, track field progress and coordinate related reports as a single event. Analytics help teams understand response performance and plan maintenance, and integrations connect operational information systems. The company also provides trained answering-service teams for after-hours and overflow calls. It serves water, sewer, electric and multi-utility operators, municipalities, public works and waste-collection services.

Irrigreen designs and manufactures smart in-ground irrigation systems combining programmable sprinkler heads, a networked controller and a mobile app. Each head adjusts its spray distance as it rotates, allowing water coverage to follow a lawn’s mapped boundaries rather than overlapping fixed circles or watering driveways and patios. The app lets homeowners customize zones and schedules, with weather-aware automation adjusting watering to local conditions. Its AI-powered YardTrace design tool uses a property address and satellite imagery to generate a customized system layout and quote. Irrigreen sells directly to homeowners and works with certified installers, offering professional or do-it-yourself installation and integration with drip-irrigation zones.

Published name: John Bertrand. Founder and CEO of Daupler, a utility-response software company. Existing same-name identities and roles, including the native 8VC adviser, are preserved.

Dionymer is an industrial-biotechnology company producing biobased, biodegradable polymer materials from food waste and agricultural by-products. It prepares waste-derived nutrients, ferments them with microorganisms that accumulate PHA biopolymers, and extracts polymer grades for powders, coatings, encapsulation and plastic applications. Its PHBV and other PHA materials aim to replace petroleum-derived polymers in cosmetics, packaging, textiles and other manufactured products. The company operates a preindustrial pilot in Mérignac and is developing an industrial demonstrator as it commercialises its materials, including Orya cosmetic powders and Orpel polymers for injection and extrusion. Announced plans for larger plants are future capacity objectives, not existing commercial output.

Previously led Total’s petrochemicals business.

Background as a junior project manager and specialisation in international business and management.

Previously worked at ExxonMobil.

Works on waste sourcing and strategic partnerships.

Background as a lead process engineer in oil and gas.

Experience following project fabrication and starting up process units.

Marketing and communications experience with business and consumer brands; works as a consultant.

Former founder and CEO of ETIA.

Holds a PhD in polymer chemistry and has experience in the petrochemical industry.

Bobine develops an electrified chemical-recycling process that converts hard-to-recycle plastic waste into olefins, including ethylene and propylene, for making new polymers. Its technology combines heterogeneous catalysis with electromagnetic induction to target chemical reactions without a conventional steam-cracking furnace. The process originated at ICPEES, a CNRS and University of Strasbourg laboratory, and is commercialised under an exclusive licence administered by SATT Conectus Alsace. Bobine is scaling from laboratory and continuous pilot operation with Michelin toward an industrial demonstrator and eventual licensed commercial units. It develops technology and process equipment for recycling and petrochemical manufacturers; commercial-scale deployment remains part of its development roadmap.

Experienced project director in major oil-and-gas projects.

Experience in pilot operations for polymer production.

Experience in administrative, accounting and human-resources management.

Background in banking in the energy sector and equity research covering oilfield services.

Process engineer with extensive petrochemistry experience. Axeleo identifies previous leadership of Arkema’s process-safety business unit.

Industrial-technology executive with experience in oil-and-gas licensing sales and leadership of a deep-technology startup. Axeleo identifies prior work at Prosernat and EMEA innovation leadership at Pall Corporation.

Jinling Zhang (张金玲) is CFO and managing partner of Baidu Ventures, as named in its current official directory. Her responsibility combines financial leadership and investment-firm management at the independent AI-focused platform. A current2026SEC issuer biography dates her Baidu Venture CFO/managing-partner tenure to November2020 and describes earlier financial leadership at Baidu Capital, Xiaomi, Cisco and Seagate. Month-only tenure information does not establish a full start date; Baidu Capital is a separate affiliation, not a merged fund manager.

Xue Gao (高雪) is CEO and managing partner of Baidu Ventures, as named in its current official directory. He leads an early-stage investment platform focused on artificial intelligence, robotics, autonomous driving, advanced computing and life sciences. The firm’s official biography and investment commentary emphasize technical innovation and applications in industry, energy, transportation and medicine. His identity is established by the named original firm portrait, rather than unrelated researchers with similar names.

Jill Lopes, CPA, identifies Tiny Orange Capital on her self-published professional profile and describes serving as Director of Finance for a family office, overseeing its financial operations. She is based in the Washington DC–Baltimore area. The exact legal employing vehicle and start date are undisclosed; no independent investment authority or personal checks are inferred.

Sam Stein’s self-published professional profile identifies Tiny Orange Capital and locates him in Washington, DC. It lists James Madison University education and participation in Madison Venture Group and the Financial Management Association. The public profile does not expose his Tiny Orange job title or employment dates; associate or portfolio-company board titles from third-party directories are not asserted.

Tiny Orange Capital’s own public LinkedIn company page lists Kara Olivarria among its affiliated employees, without title or appointment dates. Her self-published profile currently identifies New Way Academy in Phoenix and describes teaching and entrepreneurship interests. The Tiny Orange affiliation is preserved as undated and not asserted to be current investment employment.

Tiny Orange Capital’s own public LinkedIn company page lists Maribeth Bluyus among its affiliated employees, without title or appointment dates. Her newer self-published profile identifies Personal Finance Institute; therefore this is an undated published Tiny Orange association, not a claim of current employment. Her profile describes experience bringing structure, strategy and operational leadership to organizations. Durin’s July18,2025 signed SEC amendment names Maribeth Bluyus its chief executive. This dated legal disclosure follows Mert Sahin’s earlier CEO signature. Exact appointment/end dates and continuing post-acquisition employment are unknown; the May2026 release identifies Steven Verdooner as CEO of the combined NeuroVision business.

Tombot’s SEC-filed September 2022 issuer fundraising exhibit names Ric and Jean Edelman alongside Tiny Orange in its family-office investor section. The display reports USD500,000 for that family-office entry as of September 8, 2022. This is a historical named affiliation, not proof of a current operating position, separate personal check, legal ownership percentage or fund closure. Jean also publishes Self-Care with Jean.

Tiny Orange Capital is a private investment management and business consulting firm whose investment services are devoted to a single family office. Its own website publishes a focus on mid-stage venture capital, financial services, fintech, digital assets, innovative biotech and other exponential technologies. The firm also provides business management, sales, marketing, branding, media and leadership consulting, mentoring emerging enterprises, and board and advisory services. Its own public locations are Tysons Corner, Virginia; New York, New York; and Scottsdale, Arizona. The legal entity suffix, founding date, assets under management and any outside-LP fund closes are not publicly verified here. It is distinct from the unrelated Tiny/Tiny Capital business and from Edelman Financial Engines. Ric Edelman’s own December 17, 2024 announcement identifies Tiny Orange as his family office and describes expanding fintech, exponential technology and crypto investments through it. NeuroVision’s current issuer-published board biography identifies René Chaze as a Tiny Orange partner focused on blockchain, digital assets and life sciences. The issuer’s own investor section lists Tiny Orange Capital, supporting a neuroscience/biomarker-company investment relationship, but it does not disclose the check date, stage, ticket or legal investing vehicle. A board appointment alone is not treated as a personal check. The public named roster is source qualified: Ric Edelman, René Chaze, Jean Edelman in a historical 2022 issuer family-office disclosure, and Maribeth Bluyus, Kara Olivarria, Sam Stein and Jill Lopes in company or first-person professional pages. Maribeth and Kara’s newer profiles identify other employers; their Tiny Orange affiliations remain undated, with current employment unverified. Sam’s public title is not disclosed; Jill self-describes a family-office Director of Finance role. No complete current internal employee directory is published on the firm’s website. Tombot’s SEC-filed September 2022 issuer exhibit lists Tiny Orange, Ric and Jean Edelman together in a family-office investment entry of USD500,000 within the issuer’s cumulative USD4.6 million raised as of September 8, 2022. This does not establish a specific priced-round allocation, three separate checks, a private-LP vehicle or an exact cash closing date. No fund raise is inferred from family wealth, portfolio fundraising totals or affiliated financial-planning-company assets.

Arlo G. Sorensen is a longtime Whittier-family executive and trustee. Historical SEC disclosures explicitly identify him as co-trustee of seventeen trusts that were members of Whittier Ventures LLC and collectively held a majority of its membership interests, establishing voting and investment control through the trusts. This is a historical control relationship, not a current LLC employment claim or a personal investment. An issuer-published St. Martin Holdings board biography supplies his authentic named portrait and describes his retired presidency and directorship of M.H. Whittier Corporation, Whittier Trust and charitable-board service, and a 1964 accounting bachelor’s from Brigham Young University. Its published board biography identifies St. Martin service since 1998. These separately sourced affiliations do not turn the related companies into the same legal investor.

Liam J. McGuinness is Whittier Trust Company’s chief financial officer, overseeing corporate accounting, tax and client accounting. A 2025 SEC filing also explicitly identifies him as CFO of Whittier Ventures LLC, spelling his surname McGuiness; the native named Whittier Trust biography uses McGuinness and substantiates the shared identity. His LLC affiliation is last-confirmed in that filing, with no exact appointment date inferred. He joined Whittier in 2015 after corporate-finance work at Oaktree Capital Management and financial planning, analysis and systems work at Western Asset Management; earlier employers include IndyMac Bank and Deloitte. He graduated cum laude from Bucknell University with a BSBA and accounting/German double major, and holds CPA and CFA credentials. His native biography also identifies Hillsides treasurer/finance committee service. No personal investment check is inferred.

David A. Dahl is the president and CEO of Whittier Trust Company. The separate Whittier Ventures LLC is a private investment entity: a 2025 SEC filing identifies Dahl as its manager, while historical SEC filings describe him as its president from 1996. These affiliations are dated and do not transfer the trust-company roster or assets to the LLC. His native Whittier Trust biography says he joined in 1993, previously worked as a portfolio manager at Duff & Phelps Investment Management in Chicago, earned a bachelor’s from the University of San Diego and an MBA from the University of Southern California, and holds CFA and CPA credentials. His career includes board service with technology, medical, energy and charitable organizations. Corporate leadership does not imply a personal NeuroVision investment.

Whittier Ventures LLC is the private investment entity expressly named as an institutional participant in NeuroVision Imaging’s May 2, 2018 Series C first close of USD11.2million; the USD15million figure was the intended total round, not proof of additional closed cash. SEC records identify Whittier Ventures LLC separately from Whittier Trust Company, The Whittier Trust Company of Nevada, Whittier Holdings, Whittier Advisors and Whittier Energy. Historical SEC filings describe it as a private investment entity, show David A. Dahl serving as president from 1996, and identify seventeen trusts as members with Arlo G. Sorensen, their co-trustee, exercising voting and investment control because those trusts held a majority of membership interests. This is a dated historical ownership disclosure, not a claim that Sorensen personally owned or paid for the institutional investments. A 2025 FundVantage SEC filing separately identifies Dahl as a manager of Whittier Ventures LLC and Liam McGuinness (spelled McGuiness in that filing) as its CFO. Their current Whittier Trust biographies and authentic portraits corroborate the individual identities, while their LLC roles remain explicitly last-confirmed in 2025. An authentic issuer board portrait and substantive biography also identify Sorensen; his LLC control affiliation is qualified as historical. The LLC’s neuroscience-related activity includes NeuroVision’s retinal-amyloid Alzheimer’s-detection platform. SnapMD’s January 2016 issuer announcement independently names Whittier Ventures in its actual USD5.3million Series A first closing; a CEO quote in that same announcement calls the investor Whittier Trust, illustrating the affiliated platform’s public terminology without establishing identical legal buyers for every transaction. No current standalone LLC website, LLC-specific public logo, comprehensive current staff directory, external LP fund close or dedicated fund corpus was verified. Affiliate trust-company assets, Whittier Advisors’ AUM and Ambrus bond funds are not assigned to this distinct entity. No invented graphic or affiliate logo is used to fill the original-branding gap.

Beijerinvest is a Swedish family-owned investment company that invests in and develops businesses with a strong entrepreneurial culture. It combines long-term ownership with support for leadership, business development and access to financial resources. Its portfolio includes a controlling stake in listed industrial group Beijer Alma, wholly owned manufacturing and industrial-trading businesses, and around thirty investments in growth companies. It also holds research-based companies through university-related investment collaborations, including Mesenkia Therapeutics. Beijerinvest is distinct from associated philanthropic organizations such as Beijerstiftelsen and the Anders Wall Foundation.

Almi Invest Östra Mellansverige AB is a wholly owned regional venture-capital subsidiary of Almi Invest AB. It invests alongside private investors in early-stage companies in Sörmland, Uppsala, Västmanland, Örebro and Östergötland, combining equity capital with active ownership and board support. Its published portfolio includes life-science companies such as Mesenkia Therapeutics and Pixl Bio, as well as industrial and technology startups. It manages regional partnership funds financed with EU structural funds and public regional and Almi capital. This investing company is distinct from Almi Östra Mellansverige AB, which provides loans and business development.

Uppsala University Invest (UU Invest) is Uppsala University’s investment and commercialization company. It takes minority stakes in early research-based businesses and helps researchers and students validate technology, markets and business models, including projects before a company is established. It supports portfolio companies with active ownership, business development and networks of entrepreneurs, specialists and investors, using a longer investment horizon than many venture-capital firms. Its investments span life sciences, deep technology and other university-derived innovations, and investment returns are reinvested in new research-based projects. Founded in 1995, it also operates project and intellectual-property subsidiaries.

Almi Invest is the Swedish state-owned Almi group’s venture-capital organization. It co-invests with private investors in early-stage, scalable companies throughout Sweden through seven regional investment companies and a national GreenTech company. Its investment teams provide capital, board involvement and support with strategy, growth and subsequent financing. Its portfolio spans technology, deep technology, life sciences and industry, with the national GreenTech arm concentrating on businesses that reduce environmental impact. Almi Invest AB is the venture-capital parent company; regional investing entities are legally distinct from Almi’s lending and business-advisory companies.

David K. Robb was president and chief operating officer of the manager of Gaston Capital Healthcare Fund in its April2017 SEC filing. The portfolio issuer Intezyne’s own board biography describes his earlier economics and asset-allocation work at FirstChicagoInvestmentAdvisors, subsequent futures trading at TheChicagoCorporation, and entrepreneurial experience in technology, manufacturing and medical technology. He also served environmental and animal-welfare nonprofits. This is a historical Gaston affiliation: the current manager directory does not list him, and an undated legacy issuer page is not treated as confirmation of2026 payroll. His identity is distinct from other unrelated people named DavidRobb.

Kyle Radavich joined Gaston Capital as an associate in2024 and was promoted to senior associate on March13,2025, supporting investment sourcing, diligence and portfolio work. Prior positions were at FivePointsCapital and LeerinkPartners. The manager confirms a2020 BBA in finance from UniversityofWisconsinOshkosh and D3 football participation, authenticating his historical university roster photo. His newer own public profile names RoanEquity, so the Gaston website’s retained listing is not represented as verified current employment. Exact departure day remains unknown.

Don (Donald) McCaughey is a current partner at Gaston Capital. The manager’s current biography and own2018 appointment release establish that he joined in2018 after17 years at EatonVance, where he worked as a vice president and regional director. His education is BS ChapmanCollege and MBA PepperdineUniversity. The current site identifies MobilityDesigned board involvement. His career experience raising capital is not the size of a Gaston fund or a personal investment ticket.

Michael K. (Mick) McMahan is the founding partner of Gaston Capital, which he established in2006. The current manager biography describes more than35 years managing portfolios and supporting small businesses, and confirms BA and MPA degrees from the University of North Carolina at ChapelHill. The April2024 management transition expressly preserves his founding-partner role. His manager affiliation and portfolio board positions do not constitute personal cash investments.

Gaston Capital is a US private investment firm established in 2006, operating from Charlotte and Belmont, North Carolina. Its own releases identify the manager as Gaston Capital, LLC. It makes minority growth-equity investments and can invest alone or alongside other investors, focusing on healthcare, SaaS, business and financial services, and light industry. Published investment-size and EBITDA criteria are targets, not fund commitments or executed tickets. Neuroscience and deep-technology relevance is supported by NeuroVision Imaging’s current institutional investor disclosure, the manager’s behavioural-health pharmacy investment history, and its portfolio of drug-development, orthopaedic-device and mobility-technology companies; this does not imply that every portfolio business develops AI. The current manager site names founder Michael K. (Mick) McMahan, managing partner Glenn Walthall, partner Don McCaughey and Kyle Radavich. Its dated April2024 announcement establishes Walthall’s promotion from CIO. Kyle’s own newer public profile names Roan Equity, so his Gaston senior-associate affiliation is qualified as last confirmed March2025; the newer affiliation does not alone prove an exact departure or exclude concurrent roles rather than asserted current payroll. SEC2017 filings separately establish the historical president/COO affiliation of David K. Robb, who is not in the current manager roster. Sources identify distinct legal investment vehicles: Gaston Capital Healthcare Fund LLC, Gaston Capital Fund V LLC, Gaston Capital Income Fund II LLC formerly Gaston Capital Fund VI LLC, The William Gaston Fund LLC and The William Gaston Income Fund LLC. The Healthcare Fund’s latest public FormD amendment, signed February1,2019, reports USD12296053 actually sold against a USD50million offering target, with first sale March31,2017. This cumulative amount sold is not a verified final fund close; the target is excluded and the exact closing day remains NULL. Other legal vehicles have undisclosed verified closing amounts and dates. The 2026 North Carolina court opinion confirms their literal legal names and FundVI/IncomeII continuity; being co-plaintiffs does not establish equal pooled-fund structures or legal management contracts for every vehicle. Gaston Capital Partners LLLP and MKM&Company are separately named affiliated companies, not automatically additional LP funds or interchangeable contracting payers. Litigation allegations about aggregate biomedical loans are not treated as verified new fundraising or investor tickets. No registered fund closing is inferred from the manager’s USD2–10million deal-size criteria or a partner’s career capital-raising experience.

Kesmalea Therapeutics Limited is a UK preclinical drug-discovery company founded by medicinal chemist Harry Finch in2020 (company12961631, incorporated20October2020). Its SELFTAC platform uses reversible linkers to let smaller components assemble into targeted protein degraders, addressing the drug-like properties and central-nervous-system delivery limits of larger bifunctional molecules. Research targets oncology and CNS disease; brain penetration is a development objective, not a claim of clinical efficacy or regulatory approval. Robert Johnson is CEO, with published scientific, finance and discovery leaders and an independently verified board. Syncona and Oxford Science Enterprises backed its2022 SeriesA. Primary historical Syncona reporting describes GBP20M/GBP16Mcommitment, while the current issuer and Syncona page report GBP25M/GBP20Mcommitment for2022; the unresolved allocation is source-qualified rather than summed as multiple cash raises. Syncona separately reports GBP5M additional financing in2023 and a GBP4M commitment. Commitment sizes, shareholding and carrying values are distinguished from verified paid investor tickets. The company describes an internal pipeline and potential collaborations; no unsupported AI focus is asserted.

Claire Walshe joined Kesmalea in2022. Her earlier research leadership includes Mestag and Topivert; she trained in cancer immunology.

Clive Dix chairs Kesmalea. He co-founded Convergence and PowderMed and has worked in pharmacology and pharmaceutical research leadership.

Harry Finch founded Kesmalea in2020. A medicinal chemist, he previously led chemistry at GlaxoWellcome and co-invented salmeterol.

Justin Bower oversees Kesmalea discovery and technology. His background includes medicinal chemistry, Cancer Research UK research leadership and a Loughborough PhD.

Mark Fox leads Kesmalea finance. He has held financial leadership roles at Quell and Gyroscope and is CIMA qualified.

Robert Johnson leads Kesmalea. His previous roles include CEO of Adrestia, Insmed site leadership and co-founding Affinia and Alacrita.

Timothy Clackson is a Kesmalea director and former CEO of IDRx and Theseus. He previously led research and development at ARIAD.

Alexander Cheng is an associate in the current WI Harper directory, based in the San Francisco Bay Area. He works on sourcing, diligence, investment and the firm’s digital content, with interests in semiconductors and AI. Earlier he was a user interface designer and product lead at a B2B e-commerce startup. He holds a graphic design degree from the California Institute of the Arts.

Ling Hu is identified as chief financial officer and authorised signatory of WI Harper INC VI Management Limited in its April15,2025 SEC ERA Final filing. This is a last-confirmed historical legal-entity capacity; the current WI Harper public operating-team directory does not include her, and current tenure is not independently established. An authentic named portrait has not been located.

Emily Guo is a senior associate in the current WI Harper directory, working in Shenzhen and Hong Kong. She focuses on technology, robotics, IoT, media and lifestyle businesses. Earlier experience included the firm’s San Francisco office, industrial technology investing at AGIC Capital and an internship at Boston Consulting Group. She studied business administration and digital animation at the University of Southern California.

Louie Lu is a WI Harper associate in Taipei, focused on advanced materials and industrial technology investments in the United States and Asia Pacific. Before investing he worked in photochemical materials process engineering at GRECO Resin and completed a business development internship at DKSH Taiwan. He holds an MBA from National Chengchi University and a chemical engineering degree from National Taiwan University.

Eric Fu is a principal in the current WI Harper directory; the individual biography retains an older director title. His expertise covers healthcare services, medical devices, investment and portfolio management. Earlier roles included hospital acquisitions and venture investing at PKU Healthcare, healthcare policy and investment at Taikang, and venture/private equity at Jinmao Capital. He holds a medical master’s degree from Peking University and a business management master’s from Tsinghua.